TrialScribe is developed, a domain-specific harness that equips coding agents with task skills and a verification loop that improves a locally served open-weight model by 6.2-59.4 points across eight metrics, enabling it to match or surpass proprietary models such as GPT-5.6-Sol.
Jia-Cheng Lin, Geoffrey Low, Nishit Agarwal et al.· 0 citations
The Second Workshop on SciSoc Agents & LLMs: Agentic AI for Scientific and Societal Advances aims to explore the emerging paradigm of agentic artificial intelligence, where Large Language Models (LLMs) are combined with autonomous agents, tools, memory, and multi-step reasoning to drive scientific discovery and address...
Jia-Yuan Ding, Wei Jin, Carl Yang et al.· Proceedings of the 32nd ACM...· 0 citations
TrialAtlas is introduced, a memory-augmented multi-agent research organization for CDP that mirrors this collaborative process by coordinating specialized agents for literature synthesis, competitive trial intelligence, regulatory precedent analysis, and integrated reasoning over trial design and development risk.
Jia-Cheng Lin, Zifeng Wang, Zheng Chen et al.· 0 citations
It is demonstrated that integrating compact neural encoders with large language models provides a scalable and highly accurate framework for clinical NLP tasks, including SDoH extraction, and some unexpected patterns in LLM performance are observed.
Paul Landes, A. Cross, Ji-Meng Sun· International Conference on...· 0 citations
Machine learning (ML) has seen promising developments in materials science, yet its efficacy largely depends on detailed crystal structural data, which are often complex and hard to obtain, limiting their applicability in real-world material synthesis processes. An alternative, using compositional descriptors, offers a...
Namkyeong Lee, Heewoong Noh, Gyoung S. Na et al.· Proceedings of the 32nd ACM...· 0 citations
TrialGPT 2.0 is presented, an AI-assisted clinical trial recommendation system designed for real-world deployment that improves clinician efficiency and identifying frequently overlooked trial opportunities, ultimately helping to expand and accelerate accrual to cancer trials.
Yin Fang, Qiao Jin, Shubo Tian et al.· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.